Findings

What do systematic reviews say?

11 questions · 11 findings · 3 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 9.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 54.5%Moderate 3 · 27.3%High 1 · 9.1%

Chemotherapy with TKI vs chemotherapy alone

QoL · recurrent platinum‐resistant EOC

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 164 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 608 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

QoL · recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 315 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1340 participants
Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 486 participants
Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 890 participants
High

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 744 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 229 participants
Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 339 participants
Moderate